# US 2021/0171505 A1 · Substituted pyrazole-pyrimidines, variants thereof, and uses therefore

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171505 A1
- Document ID: US20210171505A1
- Status: Published application
- Kind: A1
- Application number: 17/179,705
- Filed: 2021-02-19
- Published: 2021-06-10
- Earliest claimed: 2016-12-15
- Assignees: Afferent Pharmaceuticals, Inc.
- Applicants: Afferent Pharmaceuticals, Inc.
- Inventors: Ronald Charles Hawley; Prabha Ibrahim; Anthony P. Ford; Joel R. Gever
- Web page: https://patentgrep.com/patent/US20210171505A1

## CPC

- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula I and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors: In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
ring
is selected from the group consisting of:
W is CH2, NH, N—C1-6alkylene, O or S;
X6 is N;
Y is hydrogen or —NHRd; wherein Rd is selected from the group consisting of hydrogen, C1-12alkyl, C3-12cycloalkyl, aryl, and heteroaryl; wherein each of the C1-12alkyl, C3-12cycloalkyl, aryl, and heteroaryl is optionally substituted with one to three substituents independently selected from halogen, hydroxyl and C1-6alkyl;
D is an optional oxygen;
each occurrence of R1 is independently selected from the group consisting of hydrogen, hydroxyl, C1-6alkyl, C2-6alkenyl, and C2-6alkynyl; wherein each of the C1-6alkyl, C2-6alkenyl, and C2-6alkynyl is optionally substituted with one to three substituents independently selected from halogen and hydroxyl;
each occurrence of R2 is independently selected from the group consisting of hydrogen, halogen, —NH—Rf, —C(O)—NHRf, —C(O)—C1-12alkyl, C2-12alkenyl, C2-12alkynyl, and —O—C1-12alkyl;
each occurrence of Rf is independently selected from the group consisting of hydrogen, C1-12alkyl, hydroxyl, —SO2—NH2, and —SO2—C1-6alkyl; and
R7 is selected from the group consisting of hydrogen, C1-12alkyl, and C3-12cycloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
W is CH2 or O;
X6 is N;
Y is hydrogen or —NHRd; wherein Rd is selected from the group consisting of hydrogen or C1-6alkyl; wherein the C1-6alkyl is optionally substituted with one to three substituents independently selected from halogen and hydroxyl;
D is absent;
each occurrence of R1 is independently selected from the group consisting of hydrogen and C1-6alkyl;
each occurrence of R2 is independently selected from the group consisting of hydrogen, halogen, —NH—Rf, —C(O)—NHRf, —C(O)—C1-6alkyl, C2-6alkenyl, and —O—C1-6alkyl;
each occurrence of Rf is independently selected from the group consisting of hydrogen, C1-6alkyl, hydroxyl, —SO2—NH2, and —SO2—C1-6alkyl; and
R7 is selected from the group consisting of hydrogen and C1-6alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, having formulae Ia:

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein:
W is CH2 or O;
R1 is selected from the group consisting of hydrogen and C1-6alkyl;
R2 is selected from the group consisting of hydrogen, halogen, —NH2; —C(O)—NH2, —C(O)—C1-6alkyl, and —O—C1-6alkyl; and
Rd is selected from the group consisting of hydrogen and C1-6alkyl,
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound of claim 1 having one of the following formulae Ic and Id:
or a pharmaceutically acceptable salt thereof.

### Claim at position 7

7-8. (canceled)

### Claim 9 (depends on 6)

The compound of claim 6, wherein:
W is CH2 or O;
R1 is selected from the group consisting of hydrogen and C1-6alkyl;
R2 is selected from the group consisting of hydrogen, halogen, —NH2, —C(O)—NH2, —C(O)—C1-6alkyl, and —O—C1-6alkyl; and
Rd is selected from the group consisting of hydrogen and C1-6alkyl,
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The compound of claim 1, wherein W is O,
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The compound of claim 1, wherein W is CH2,
or a pharmaceutically acceptable salt thereof.

### Claim 12

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof,
wherein: R is selected from the group consisting of hydrogen, hydroxyl, C1-6alkyl, C2-6alkenyl, and C2-6alkynyl; wherein each of the C1-6alkyl, C2-6alkenyl, and C2-6alkynyl is optionally substituted with one to three substituents independently selected from halogen and hydroxyl.

### Claim 13 (depends on 1)

A composition which comprises an inert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A method for treating a P2X3 and/or P2X2/3 associated disease or disorder, comprising administering to a subject in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 16

(canceled)

### Claim 17 (depends on 3)

The compound of claim 3, wherein:
W is CH2 or O;
R1 is selected from the group consisting of hydrogen and C1-6alkyl;
R2 is selected from the group consisting of hydrogen, halogen, —NH2; —C(O)—NH2, —C(O)—C1-6alkyl, and —O—C1-6alkyl; and
Rd is selected from the group consisting of hydrogen and C1-6alkyl,
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The compound of claim 17, wherein W is CH2,
or a pharmaceutically acceptable salt thereof.

### Claim at position 18

19-20. (canceled)
